Abstract
We note with great interest the publication by Stern et al, which evaluated the hypothesis that human leukocyte antigen (HLA) DR15 would reduce relapse rate and improve survival in patients receiving allogeneic stem cell transplantation [1]. We had previously examined this hypothesis in our single center study of 119 consecutive related and 48 consecutive unrelated myeloablative allogeneic blood and marrow transplant (BMT) for myeloid malignancies to investigate the influence of HLA DR15 on overall survival (OS), progression-free survival (PFS), and incidence of grades II to IV acute graft-vs-host-disease (GVHD) [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
